Sam Brusco, Associate Editor06.21.23
Mediso has achieved U.S. Food and Drug Administration (FDA) clearance for its InterView FUSION and InterView multimodality (PET/SPECT/MRI/CT) image processing and reporting software, adapted for nuclear medicine and molecular imaging workflows.
The software is a complete solutions for image visualization, post-processing, and reporting adapted for routine nuclear medicine and molecular imaging. Specialized tools cover bone, cardiac, central nervous system, thyroid, parathyroid, kidney, liver, digestive system and lung.
The software boosts SPECT image quality with iterative reconstruction and reaches absolute quantitation with Tera-Tomo SPECT reconstruction engine for fast, accurate dosimetry. Modules help enhance clinical and preclinical research like automatic lesion detection, automatic segmentation, and image denoising.
The InterView software, according to Mediso, integrates to any hospital information system, either running on a standalone workstation or on a physical or virtualized server.
"Receiving the FDA nod for our image processing software marks the next step in marketing our clinical products in the USA," Istvan Bagamery, founder and CEO of Mediso told the press. "The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application and they demonstrate our continuous commitment to the molecular imaging market."
Mediso has over 1,500 commissioned nuclear medicine systems worldwide.
The software is a complete solutions for image visualization, post-processing, and reporting adapted for routine nuclear medicine and molecular imaging. Specialized tools cover bone, cardiac, central nervous system, thyroid, parathyroid, kidney, liver, digestive system and lung.
The software boosts SPECT image quality with iterative reconstruction and reaches absolute quantitation with Tera-Tomo SPECT reconstruction engine for fast, accurate dosimetry. Modules help enhance clinical and preclinical research like automatic lesion detection, automatic segmentation, and image denoising.
The InterView software, according to Mediso, integrates to any hospital information system, either running on a standalone workstation or on a physical or virtualized server.
"Receiving the FDA nod for our image processing software marks the next step in marketing our clinical products in the USA," Istvan Bagamery, founder and CEO of Mediso told the press. "The InterView software together with the AnyScan SPECT and SPECT/CT clinical systems provide a complete solution for all nuclear medicine routine and research application and they demonstrate our continuous commitment to the molecular imaging market."
Mediso has over 1,500 commissioned nuclear medicine systems worldwide.